Xbrane And Stada’s Ranibizumab Snapped Up In North America
Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada
Executive Summary
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.
You may also be interested in...
Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA
Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.
Xbrane Refiles Ranibizumab With US FDA
Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.
Stada And Xbrane Receive MHRA Nod For Ranibizumab
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.